Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4274-4280
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4274
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4274
Conversion therapy in advanced perihilar cholangiocarcinoma based on patient-derived organoids: A case report
Yong-Gang He, Jing Li, Zheng Wang, Chong-Yu Zhao, Lu Zheng, Xiao-Bing Huang, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Ling-Yu Zhang, School of Clinical Oncology, Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, Fujian Province, China
Ling-Yu Zhang, Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China
Co-first authors: Yong-Gang He and Ling-Yu Zhang.
Co-corresponding authors: Lu Zheng and Xiao-Bing Huang.
Author contributions: He YG and Zhang LY were responsible for writing the manuscript; Li J, Wang Z, and Zhao CY were responsible for data acquisition and investigation; Zheng L and Huang XB reviewed the manuscript; All authors contributed to the study and approved the submitted version.
Supported by the Chongqing Natural Science Foundation Project , No. CSTB2022NSCQ-MSX0172 .
Informed consent statement: The patient provided the written informed consent to participate in this study. Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu Zheng, MD, PhD, Chief Doctor, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, No. 83 Xinqiaozheng Street, Shapingbei District, Chongqing 400037, China. zhenglu@tmmu.edu.cn
Received: April 26, 2024
Revised: August 20, 2024
Accepted: August 28, 2024
Published online: October 15, 2024
Processing time: 152 Days and 21.5 Hours
Revised: August 20, 2024
Accepted: August 28, 2024
Published online: October 15, 2024
Processing time: 152 Days and 21.5 Hours
Core Tip
Core Tip: The patient-derived organoids (PDOs) have been demonstrated to predict the response to drugs in multiple cancer types. Here we first descried a patient with advanced perihilar cholangiocarcinoma (pCCA) who successfully underwent surgical resection after use of the PDO-guided gemcitabine and cisplatin in combination with toripalimab and lenvatinib and achieved good prognosis. For advanced pCCA patients, the PDO-based drug sensitivity testing contributes to screening effective chemotherapy drugs to promote the personalized treatment, which not only creates opportunities for surgical resection by lessening the tumor, but also offers a novel platform for improving the patient’s prognosis.